Malignant News and Research

RSS

Recommendations for prostate cancer prevention and treatment

In light of Prostate Cancer Awareness month, integrative medicine pioneer and cancer expert Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer. As a well known specialist in the field of integrative prostate cancer therapy, Dr. Eliaz strategically combines ancient and modern healing modalities into a holistic practice of medicine by successfully incorporating the most effective and well researched therapies available in conventional and complementary medicine.

21 Sep 2010

LA surgeon develops minimally invasive approach to remove pineal tumors

One of the most difficult-to-remove tumors located deep in the midbrain area can now be safely excised thanks to the work of one Los Angeles surgeon. Hrayr Shahinian, M.D., medical director of The Skull Base Institute in Los Angeles, has developed a minimally invasive approach to removing pineal tumors so called as they are shaped like pine cones.

21 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

Researcher discover enzyme for brain tumor malignancy

Tom Wurdinger, a Dutch researcher who is connected to Harvard (Boston) and the VUmc Cancer Center in Amsterdam, has discovered the enzyme playing a very important role in the return of malign brain tumor after surgery and radiation. By making this enzyme inactive, the cancer cell can become disorganized and blow itself up.

17 Sep 2010

Professor named recipient of 2010 Phoenix Award Glass Person of the Year

Dr. Delbert Day, Curators' Professor emeritus of materials science and engineering at Missouri University of Science and Technology, has been named the 2010 Phoenix Award Glass Person of the Year, the glass industry's top honor. The Phoenix Award is given annually to a living person who has made outstanding contributions to the industry.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.

16 Sep 2010

Veracyte presents FNA clinical trial data at International Thyroid Congress

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France.

16 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

Researchers develop ChIP Enrichment Analysis to identify drug targets, biomarkers

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.

16 Sep 2010

ESMO honors eminent cancer specialists

15 Sep 2010

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy.

15 Sep 2010

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

SCIENTISTS have discovered for the first time that studying calcium deposits in the breast, often detected through screening, could help doctors diagnose breast cancer more effectively.The study, published in the British Journal of Cancer today (Wednesday), examined the relationship between the composition of these deposits found in breast tissue and the malignancy of a tumour.

15 Sep 2010

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

Physicians have long noticed that breast cancer patients who have had surgery or radiation therapy have an heightened risk of developing angiosarcoma, a rare type of cancer that originates in the lining of the blood vessels.

14 Sep 2010

Myconostica presents data of MycAssay for Pneumocystis detection

Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the Company's CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.

13 Sep 2010

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.

13 Sep 2010

Men with low PSA level does not benefit further treatment: Study

Men aged 55 to 74 years who have low baseline blood levels of prostate specific antigen (PSA) are not likely to benefit from further screening and treatment. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The aim of the study is to help physicians and patients weigh the pros and cons of prostate cancer screening and early detection.

13 Sep 2010

Sun tanning still in demand for Victorian teenagers: Survey

According to the latest survey Victorian teenagers, despite skin cancer warnings, are still keen on getting a sun tan. The online survey by SunSmart showed that young Victorians are significantly more sun-safe than they were when the Slip! Slop! Slap! campaign first started 30 years ago.

12 Sep 2010

Translational Research issue focuses field of stem cell research, therapy

The use of stem cells for research and their possible application in the treatment of disease are hotly debated topics. In a special issue of Translational Research published this month an international group of medical experts presents an in-depth and balanced view of the rapidly evolving field of stem cell research and considers the potential of harnessing stem cells for therapy of human diseases including cardiovascular diseases, renal failure, neurologic disorders, gastrointestinal diseases, pulmonary diseases, neoplastic diseases, and type 1 diabetes mellitus.

10 Sep 2010

Malignant News and Research

Recommendations for prostate cancer prevention and treatment

LA surgeon develops minimally invasive approach to remove pineal tumors

Conference to discuss frontline of immunological research, its clinical application

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Researcher discover enzyme for brain tumor malignancy

Professor named recipient of 2010 Phoenix Award Glass Person of the Year

ESMO honors three eminent cancer specialists for their contribution towards medical research

JAK oral medication produces lasting relief for patients with myelofibrosis: Researchers

Veracyte presents FNA clinical trial data at International Thyroid Congress

Johns Hopkins offers sources who can answer queries on prostrate cancer

Researchers develop ChIP Enrichment Analysis to identify drug targets, biomarkers

ESMO honors eminent cancer specialists

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

Scientists discover study of calcium deposits helps effective breast cancer diagnosis

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

Myconostica presents data of MycAssay for Pneumocystis detection

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Men with low PSA level does not benefit further treatment: Study

Sun tanning still in demand for Victorian teenagers: Survey

Translational Research issue focuses field of stem cell research, therapy

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News